Serviceeinschränkungen vom 12.-22.02.2026 - weitere Infos auf der UB-Homepage

Treffer: Use of High-Flow Nasal Cannula Oxygen Therapy in Subjects With ARDS: A 1-Year Observational Study.

Title:
Use of High-Flow Nasal Cannula Oxygen Therapy in Subjects With ARDS: A 1-Year Observational Study.
Authors:
Messika J; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France. Institut National de la Santé et de la Recherche Médicale, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Paris, France and with Université Paris Diderot, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Sorbonne Paris Cité, Paris, France., Ben Ahmed K; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France., Gaudry S; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France. Institut National de la Santé et de la Recherche Médicale, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Paris, France and with Université Paris Diderot, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Sorbonne Paris Cité, Paris, France., Miguel-Montanes R; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France., Rafat C; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France., Sztrymf B; Assistance Publique-Hôpitaux de Paris, Hôpital Antoine Béclère, Service de Réanimation Médico-Chirurgicale, Clamart, France., Dreyfuss D; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France. Institut National de la Santé et de la Recherche Médicale, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Paris, France and with Université Paris Diderot, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Sorbonne Paris Cité, Paris, France., Ricard JD; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, Colombes, France. Institut National de la Santé et de la Recherche Médicale, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Paris, France and with Université Paris Diderot, Infection, Antimicrobiens, Modélisation, Evolution, Unité Mixte de Recherche 1137, Sorbonne Paris Cité, Paris, France. jean-damien.ricard@lmr.aphp.fr.
Source:
Respiratory care [Respir Care] 2015 Feb; Vol. 60 (2), pp. 162-9. Date of Electronic Publication: 2014 Nov 04.
Publication Type:
Journal Article; Observational Study
Language:
English
Journal Info:
Publisher: Mary Ann Liebert Country of Publication: United States NLM ID: 7510357 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1943-3654 (Electronic) Linking ISSN: 00201324 NLM ISO Abbreviation: Respir Care Subsets: MEDLINE
Imprint Name(s):
Publication: 2025- : [New Rochelle, NY] : Mary Ann Liebert
Original Publication: Philadelphia : Lippincott, c1971-
MeSH Terms:
Noninvasive Ventilation* , Oxygen Inhalation Therapy*/statistics & numerical data, Respiratory Distress Syndrome/*therapy , Respiratory Insufficiency/*therapy, Acute Disease ; Adult ; Aged ; Catheters ; Female ; Humans ; Intensive Care Units ; Intubation, Intratracheal ; Male ; Middle Aged ; Nose ; Oxygen/administration & dosage ; Oxygen/blood ; Partial Pressure ; Respiratory Distress Syndrome/complications ; Respiratory Insufficiency/etiology ; Retrospective Studies ; Severity of Illness Index ; Time Factors ; Treatment Failure
Comments:
Comment in: Respir Care. 2015 Feb;60(2):307-8. doi: 10.4187/respcare.03871. (PMID: 25634883)
Comment in: Respir Care. 2015 Aug;60(8):e148. doi: 10.4187/respcare.04147. (PMID: 26211009)
Comment in: Respir Care. 2015 Aug;60(8):e148-9. doi: 10.4187/respcare.04314. (PMID: 26211010)
Contributed Indexing:
Keywords: acute respiratory failure; high flow; noninvasive ventilation; outcome; oxygen therapy
Substance Nomenclature:
S88TT14065 (Oxygen)
Entry Date(s):
Date Created: 20141106 Date Completed: 20160509 Latest Revision: 20220311
Update Code:
20250114
DOI:
10.4187/respcare.03423
PMID:
25371400
Database:
MEDLINE

Weitere Informationen

Background: Beneficial effects of high-flow nasal cannula (HFNC) oxygen on oxygenation and respiratory parameters have been reported in a small number of subjects with acute respiratory failure (ARF). We aimed to evaluate its effect in subjects with ARDS.
Methods: This was an observational single-center study. Prospectively obtained data were retrospectively analyzed. All patients admitted over 1 y to a university hospital medicosurgical ICU were included. Classification was according to the highest ventilatory support required. HFNC indications were reviewed, and demographics, clinical characteristics, and course of subjects with ARDS according to intubation need were compared.
Results: Of 607 subjects admitted, 560 required ventilatory or oxygen support, among whom 180 received noninvasive ventilatory support. HFNC was used in 87 subjects and as first-line treatment in 51 subjects (29% of first-line noninvasively treated subjects), 45 of which had ARDS (PaO2 /FIO2 of 137 mm Hg; 22 men, 57.9 y of age). Pneumonia accounted for 82% of ARDS causes. The intubation rate in these subjects was 40%. Higher Simplified Acute Physiology Score II (SAPS II; 46 vs 29, P=.001), occurrence of additional organ failure (76% vs 26%, P=.002), mainly hemodynamic (50% vs 7%, P=.001) or neurological (22% vs 0, P=.01), and trends toward lower PaO2 /FIO2 and higher breathing frequency after HFNC initiation were evidenced in subjects who failed HFNC. Higher SAPS II scores were associated with HFNC failure in multivariate analysis.
Conclusions: In daily care, over one fourth of subjects requiring noninvasive ventilatory support were treated via HFNC, with a high success rate in subjects with severe ARDS. We conclude that HFNC may be considered as first-line therapy in ARF, including patients with ARDS.
(Copyright © 2015 by Daedalus Enterprises.)